Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: A review of the current literature

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 85-92

  Walensky, Rochelle P ^a,b,c   Ciaranello, Andrea L ^a   Park, Ji Eun ^a   Freedberg, Kenneth A ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG MONITORING; HIV INFECTIONS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; RNA, VIRAL;

EID: 77953763790     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653119     Document Type: Review

References (30)

1. Kimmel AD, Losina E, Freedberg KA, Goldie SJ. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ 2006;84:581-588.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. 2006. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 18 November 2009.
3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-I-infected adults and adolescents. 2008. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL. pdf. Accessed 18 November 2009.
4. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. http://www.who.int/entity/hiv/pub/ arv/rapid-advice-art.pdf. Accessed 3 December 2009.
5. Harries AD, Schoulen EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006;367:1870-1872. (Pubitemid 43833194)
6. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Côte d'Ivoire. N Engl J Med 2006;355:1141-1153. (Pubitemid 44394920)
7. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21:1333-11140
8. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007;46:91-100. (Pubitemid 47507438)
9. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451. (Pubitemid 351635534)
10. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008;168:1910-1918.
11. Ministry of Health Malawi. Guidelines for the use of antiretroviral therapy in Malawi. 2008. http://www.hivunitmohmw.org/Main/AntiretroviralTherapy. Accessed 18 November 2009.
12. United Republic of Tanzania Ministry of Health. National guidelines for the management of HIV and AIDS. 3rd ed. Jacana, South Africa: National Department of Health, 2008.
13. South Africa National Department of Health. National antiretroviral treatment, guidelines. 2004. http://hivinsite.ucsf.edu/doc/cr09-sf-01.doc. Accessed 18 November 2009.
14. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42:464-469. (Pubitemid 44050895)
15. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151:157-166.
16. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
17. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14:259-265.
18. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. 2001. http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed 18 November 2009.
19. World Health Organization. Choosing interventions that are cost effective: cost-effectiveness thresholds. 2005. http://www.who.int/choice/costs/ CER-thresholds/en/index.html. Accessed 18 November 2009.
20. International Monetary Fund. World economic outlook database. 2009. http://imf.org/external/pubs/ft/weo/2009/02/weodata/index.aspx. Accessed 13 November 2009.
21. The Global Fund. The Global Fund to Fight AIDS, Tuberculosis and Malaria. 2009. http://www.theglobalfund.org/en/. Accessed 18 November 2009.
22. PEPFAR. United States President's Emergency Plan for AIDS Relief. 2009. http://www.pepfar.gov/. Accessed 18 November 2009.
23. World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy. 2006. http://www.who.int/3by5/capacity/ ptmonguidelinesfinalv1.PDF. Accessed 18 November 2009.
24. Clinton HIV/AIDS Initiative. Antiretroviral (ARV) price list. 2009. http://www.clintonfoundation.org/files/chaiarvpricelistaugust2009english.pdf. Accessed 3 December 2009.
25. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010;375:123-131.
26. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART Trial) In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Geneva: International AIDS Society, 2009. Abstract TUSS103.
27. Gilks CF. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe. In: Program and abstracts of the 5th International AIDS Soctiety Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Geneva: International AIDS Society, 2009. http://www.ias2009.org/ PAGMaterial/TUSS104-Gilks-1.ppt.
28. Meya D, Spacek LA, Tibenderana H, et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009;12:3.
29. US Census Bureau. Consumer Price Index detailed reports. 2009. http://www.bls.gov/cpi/cpi-dr.htm. Accessed 13 November 2009.
30. Walensky RP, Freedberg KA, Weinstein MC. Monitoring of antiretroviral therapy in low-resource settings [letter]. Lancet 2008;372:288. (Pubitemid 352020428)